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Edited by Jesus AvilaAbstract Beta amyloid (Ab) is believed one of the major patho-
gens of Alzheimers disease (AD), and the reduction of Ab is con-
sidered a primary therapeutic target. Immunization with Ab can
reduce Ab burden and pathological features in transgenic AD
model mice. Transgenic potato plants were made using genes
encoding 5 tandem repeats of Ab1–42 peptides with an ER reten-
tion signal. Amyloid precursor protein transgenic mice (Tg2576)
fed with transgenic potato tubers with adjuvant showed a pri-
mary immune response and a partial reduction of Ab burden in
the brain. Thus, Ab tandem repeats can be expressed in trans-
genic potato plants to form immunologically functional Ab,
and these potatoes has a potential to be used for the prevention
and treatment of AD.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Alzheimers disease (AD) is a neurodegenerative disorder
that is characterized by memory loss and cognitive impair-
ments in the elderly [1]. The pathological hallmarks of AD
are neuritic plaques and neuroﬁbrillary tangles. Neuritic pla-
ques are extracellular deposits of ﬁbrils and amorphous
aggregates of amyloid b (Ab) peptides. Neuroﬁbrillary tan-
gles are intracellular ﬁbrillar aggregates of the microtubule-
associated protein tau that exhibit hyperphosphorylation
and oxidative modiﬁcations [2]. Genetic and pathological evi-
dence strongly supports the amyloid cascade hypothesis ofAbbreviations: AD, Alzheimers disease; Ab, beta amyloid; APP,
amyloid precursor protein; CTB, cholera toxin B; ELISA, enzyme
linked immunosorbent assay; 5Ab42, tandem repeat 5mer of Ab1–42;
T-DNA, transfer DNA
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doi:10.1016/j.febslet.2005.11.003AD [3]. The accumulation and aggregation of Ab appears
to damage neurons, which leads to the degeneration of syn-
apses and, eventually, neuronal death. Tau pathology, which
contributes substantially to the disease process through
hyperphosphorylated tau and tangles, is triggered by Ab1–
42.
The current standard of care for mild to moderate AD
includes treatment with acetylcholine esterase inhibitors to
improve cognitive function [4], and Memantine, an N-methyl-
D-aspartate antagonist, has been approved in the US and some
other countries for the treatment of advanced AD. All of these
drugs are of limited beneﬁt to most patients because they have
only modest eﬀects on the symptoms of AD. Currently, no
treatment that has strong disease modifying eﬀects is available.
Drugs are currently being developed which target speciﬁc
sites in the amyloid cascade. Several secretase inhibitors have
been tested for their abilities to reduce Ab generation. c-Secre-
tase inhibitors, however, often failed this test because of block-
ing NOTCH signaling pathways [5]. BACE1 (b-secretase)
inhibitors may prove beneﬁcial in reducing the production of
Ab, because BACE1 knockout mice showed reduced Ab pro-
duction and do not exhibit any abnormal phenotypes [6].
Other approaches to reducing Ab aggregation in the brain in-
clude the use of chelators and small molecules with aﬃnities to
Ab [7]. One promising approach to preventing and treating
AD is based upon stimulating the immune system to remove
Ab from the brain [8]. Several strategies, including active
and passive immunization, have been examined. The initial re-
ports that immunization with aggregates Ab1–42 or passive
immunization with anti-Ab antibodies results in the clearance
of Ab plaques from the brains of amyloid precursor protein
(APP)-mutant transgenic mice were followed by several re-
ports which found that such immunizations can restore cogni-
tive deﬁcits in transgenic mice [9–12]. Although immunization
studies show promising results in APP transgenic mice without
any detectable adverse eﬀects, the recent extension of this ap-
proach to AD patients resulted in the development of menin-
goencephalitis, a potentially deadly inﬂammation of the
brain and surrounding membrane, in a small, but unacceptable
portion of patients [13]. This called attention to the issue of the
reﬁnement of immunization methods to AD researchers. Much
progress has been made in designing a vaccine which is appro-
priate for human use [14–19]. Nonetheless, an eﬀective vaccineblished by Elsevier B.V. All rights reserved.
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the most exciting ﬁelds in AD research.
Transgenic plant systems represent an alternative method
for the expression of recombinant antibodies, antigens, and
therapeutics. During the last 10 years, a host of antigens have
been successfully expressed in plants and orally delivered to
animals, resulting in enhanced immunogenicity. These antigens
include the disease-related virus capsid and surface proteins,
and pathogenic bacterial antigens [20–22]. The successful
development of a potato-derived vaccine would allow manu-
factures to meet huge, steady demands.
Here, we report our study of plant-derived human Ab used
in an edible vaccine designed to elicit a speciﬁc Ab immune re-
sponse. We generated transgenic potatoes which expressed 5
tandem repeats of Ab1–42 (5Ab42), under various control
schemes. We used the M35I mutated form of Ab1–42, which
causes less oxidative stress in cells than does wild type Ab1–
42. AD model mice (Tg2576) were vaccinated by oral gavage
with extracts of transgenic potatoes plus cholera toxin B
(CTB). The Ab-immunized mice were found to have generated
antibodies against Ab, and showed reduced numbers of Ab
plaques in their brains.2. Materials and methods
2.1. Generation of the tandem repeats form of Ab1–42
APP695 cDNA in pCB6 (a gift from Dr. Sisodia at the University of
Chicago) was used as a template for the preparation of Ab1–42 cDNA.
In order to ameliorate the toxicity normally associated with wild-type
Ab1–42, we used the mutant b-amyloid, in which the methionine at the
35th sequence has been substituted with isoleucine (M35I). The muta-
tion was generated using the Quickchange mutagenesis kit (Stratagene,
La Jolla, CA) according to the instructions of the manufacturer. Spe-
ciﬁc primers, each of which contained the AlwNI enzyme cleavage site
(underlined), were designed for the purpose of PCR ampliﬁcation (for-
ward primer; 5 0-TGA CAG ATG CTG GAT GCA GAA TTC CGA-
3 0, backward primer; 5 0-TAA CAG ATG CTG CGC TAT GAC AAC
ACC-3 0). The ampliﬁed Ab1–42 PCR products were then digested with
the AlwNI enzyme, and they were then ligated to produce the multi-
meric form. After gel elution of the multimeric form of DNA (approx-
imately 4–5mer), DNA was introduced into the AlwNI site of the
pET31b(+) vector (Novagen, Madison, WI). Cloning of the tandem re-
peats of wild-type Ab and mutant Ab was performed at the same time.
Each of 5 tandemly repeated Ab1–42 containing clones (pET31b-
5Ab42) were isolated and conﬁrmed via DNA sequencing and Western
blotting, using the Ab-speciﬁc antibody, 4G8 (Signet Lab., Dedham,
MA). In order to compare wild-type Ab with mutant Ab, the aggrega-
tion ability and cytotoxicity of each 5Ab42 were tested. Aggregation of
5Ab42 was measured by the thioﬂavin T (ThT)-binding assay, in which
the ﬂuorescence intensity reﬂects the degree of Ab ﬁbril formation [23].
Three lM of each of the synthetic Ab1–42, wild-type 5Ab42 and mu-
tant form 5Ab42, was incubated in PBS for 1 h. ThT solution (5 lM)
was added to each reaction. The resulting ThT ﬂuorescence was mea-
sured using excitation and emission wavelengths of 440 and 485 nm,
respectively (Saﬁre, TECAN, Austria). To explore the cytotoxicity,
tandem repeat 5Ab42 was challenged in HT22 murine cell culture.
Twenty-ﬁve lM of each of the aggregated Ab was used. Cell viability
was determined by MTT (methylthiazol-2-yl-2,5-diphenyl tetrazolium
bromide) assay [24]. The survival rate from 5Ab42-challenged cells
was calculated and compared to synthetic Ab25–35-challenged cells.
After the characterization of the Ab proﬁles of the wild-type and the
mutated form, we used the mutated form of Ab for further studies.
2.2. Construction of a plant expression vector and transformation into
potato
The tandem-repeated Ab gene, intended for ligation into a plant
expression vector, was ampliﬁed from the pET31b-5Ab42(M) clone
using two primers: 1. Ab F primer (5 0-GGT ACC GGA TCC GCCATG GAT GCA GAA-3 0), to which KpnI, the BamHI restriction site,
and the start codon (boxed) were added; 2. AbR primer (5 0-GAG
CTC GGA TCC AAC TCA CGC TAT GAC-3 0), to which SacI, the
BamHI restriction site, and a stop codon (boxed) were added. A single
ampliﬁcation product, with an expected size of 5mer of Ab (denoted as
5Ab), was puriﬁed and subcloned into TopoTA (Invitrogen, Carlsbad,
CA) in order to generate Topo5Ab, which was then conﬁrmed by
DNA sequencing. The 694-bp BamHI fragment of Topo5Ab was then
cloned into pMBP1 [25], which yielded pMBP5Ab. Additionally, the
KpnI/SacI fragment of Topo5Ab was cloned into pAT1 (provided by
Dr. G.H. Harn, NongwooBio, Korea), which yielded pAT5Ab. The
5Ab PCR product was ampliﬁed with another forward primer (5 0-
TGA GTC GAC GAT GCA GAA TTC CGA CAT GAC TCA-3 0),
which added the SalI site, and another reverse primer (5 0-TAA TCT
AGA TCA AAG CTC ATC CTT CTC AGA CGC TAT GAC AAC ACC
GCC-3 0), which added a sequence coding for SEKDEL (boxed) and
an XbaI site. We then cut this product with SalI/XbaI, and subcloned
it into pRTL2 [26] to make pRTL-5AbS. The HindIII fragment from
pRTL-5AbS was then cloned into pBIN19 (Clontech, Mountain View,
CA), which yielded the pE5AbS vector.
These vectors were then transformed into Agrobacterium tumefaciens
LBA4404. The in vitro grown leaf explants (Solanum tuberosum cv.
Desiree) were then co-cultured in an Agrobacterium suspension. The
regenerated shoots from the leaf explants were cultured in MS medium
(Life Technologies, Gaithersburg, MD), which yielded 1 g of microtu-
bers. At the same time, small plants were transplanted to a greenhouse,
in which they were allowed to grow naturally. The microtubers and
mature-tubers were harvested after 2 months, and were used in further
analyses. The transgenic shoots were initially selected based on the de-
gree of their resistance to kanamycin. To conﬁrm the presence of the
5Ab gene, PCR analysis was performed.
2.3. Nucleic acid extraction and analysis
Total RNA from the tubers of the transformed plants was isolated
using the RNAgents total RNA isolation system (Promega, Madison,
WI) according to the instructions of the manufacturer. In order to ﬁnd
Ab gene expression, Northern blot analysis was conducted with 30 lg
of total RNA from each transformed potato. Genomic DNAs from
pE5AbS-derived transformants were isolated and digested with SalI
and transferred to nitrocellulose ﬁlter paper. Southern blot analysis
was performed with a Dig-labeled Ab1–42 gene as a probe.
2.4. Protein extraction and analysis
Proteins from the tubers were obtained by homogenization in a mor-
tar and pestle with liquid nitrogen as described in a previous study [27].
Western blot analysis was performed with 4G8 antibody. The recom-
binant 5Ab protein levels were determined via direct ELISA assays.
The ELISA plates were coated with 100 lg of TSP in 0.05 M carbon-
ate–bicarbonate (pH 9.6) buﬀer and incubated with monoclonal anti-
Ab1–42 speciﬁc antibody (6E10, 1:1000 dilution). The amount of Ab
proteins in TSP was estimated using direct ELISA with Ab1–42 pep-
tide as a standard.2.5. Vaccination of Tg2576 with transformed plant extract
A group of transgenic mice which expressed human APP (Tg2576),
all of which were 15 months old, was used in the immunization exper-
iments. Ten mice from each group were fed tubers from transgenic po-
tato lines pE5AbS #2, and control non-transgenic potatoes plus CTB
as an adjuvant. Each mouse was gavaged approximately 25 mg of
transgenic plant extracts plus 10 lg CTB (C9903, Sigma, St. Louis,
MO) once a week for three consecutive weeks. Blood samples were ob-
tained on day 0, and then 3, 5 and 7 weeks after primary immuniza-
tion. All blood samples were analyzed by direct ELISA assay. Seven
weeks after primary immunization, the transgenic mice were boosted
by intraperitoneal injection with 15 lg of synthetic Ab1–42 peptide
emulsiﬁed in alum [22]. Sera were collected from the mice 2 weeks after
boosting, and were evaluated by direct ELISA assay.2.6. Direct ELISA for anti-Ab antibody production
In order to measure the anti-Ab antibody titers in the sera of immu-
nized mice, we coated ﬂat-bottom ELISA plates overnight at 4 C with
Ab1–42 [0.1 lg/well in 0.05 M carbonate–bicarbonate buﬀer (pH 9.6)].
The plates were washed three times in PBS-T (phosphate-buﬀered
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(RT) with 3% BSA in PBS. The plates were then washed three times,
and incubated with serum samples diluted to 1:100 in blocking buﬀer
for 2 h at RT, with agitation. The plates were washed three times
and incubated with mouse IgG-conjugated horseradish peroxidase
(secondary antibody) for 2 h at RT. The plates were washed an addi-
tional three times, and were then incubated with 100 ll of TMB
substrate (Pierce, Rockford, IL) and H2O2 for 30 min at RT. After
incubation, the reaction was measured at 450 nm with an ELISA
reader.
2.7. Plaque reduction assay
In order to determine the degree to which the amyloid plaques in the
transgenic mice had been reduced, we stained sections from the hippo-
campal regions of the left hemisphere of the mouse brains with Congo
Red. When stained with Congo Red, amyloid plaques appear pink un-
der the microscope. Digital images were taken using a digital camera
(Olympus Camedia, C-5050). Images from ten sections of each animal
were analyzed using Meta-Morph software. The percentage of the area
covered by plaques (Ab burden) was calculated from the image data.
The number of plaques in the deﬁned area and the average plaque size
were computed by a computer program in a given parameter [28]. All
of the quantitative morphological data were analyzed by one-way AN-
OVA. A P-value less than 0.05 indicated a statistically signiﬁcant dif-
ference.Fig. 1. Construction and characterization of 5Ab42. (A) Human Ab1–42 seq
replaced by Ile. (C) Multimer formation was visualized in agarose gel staine
5Ab42. KSI, ketosteroid isomerase gene for protein solubility; His, 6·His a
After IPTG induction, total extracts (t) were bound to a nickel aﬃnity col
protein (e) was analyzed by SDS–PAGE. (F) Western blot result of eluted 5A
incubated in PBS for 1hr. The aggregation was monitored by ThT ﬂuorescenc
peptide. The cell survival rates were recorded by MTT assay. The 5Ab42
P < 0.05, Student t test).3. Results
3.1. Construction of 5 tandem repeats Ab1–42 and
characterization of its product from Escherichia coli
According to recent studies conducted by McGowan et al.
[29], mice overexpressing Ab1–42 develop an AD-like pheno-
type, but this does not occur in mice expressing Ab1–40. This
ﬁnding clearly demonstrates that Ab1–42 is major causative
agent in the pathology of AD. Ab1–42 aggregates itself and in-
duces oxidative stress in the brain. The 35th methionine of
Ab1–42 seems to lie in the middle of the oxidative stress-signal-
ing pathway associated with AD [30]. Therefore, the Ab1–42
mutant form is thought to be less toxic than the wild-type pep-
tide. In recent vaccine studies, some of patients have developed
meningoencephalitis [13]. We tried to solve this problem by
using a mutated form of Ab1–42 and through the development
of an edible vaccine. At the outset, the mutation was intro-
duced to Ab1–42, replacing Met with Ile at position 35
(Fig. 1A and B). The multimer form of Ab1–42 was success-
fully isolated and cloned into pET31b(+) vector (Fig. 1C and
D) for 5Ab42 production in E. coli. The multimer form ofuence. The 35th Methionine (Met) is underlined. (B) The 35th Met was
d by ethidium bromide. (D) Structure of E. coli expression vector for
ﬃnity tag for puriﬁcation. (E) Production and puriﬁcation of 5Ab42.
umn. Column-bound proteins (b) were eluted with imidazole. Eluted
b42. (G) Ab aggregation activity test. Each of the 3 lM proteins was
e. (H) Ab toxicity test. HT22 cells were challenged with 25 lM of each
peptide has no detectable cytotoxicity (statistically signiﬁcant result,
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comparison with mutant Ab1–42 (data not shown). In order
to determine whether the mutated 5Ab42 retains immunoge-
nicity, Western blot analysis was conducted with puriﬁed
5Ab42 protein with an Ab-speciﬁc antibody, 4G8. The ex-
pressed 5Ab42 exhibited a speciﬁc band of the expected size
(Fig. 1E and F). Both the mutated form and the wild-type
5Ab42 aggregated eﬃciently in PBS. No diﬀerence was shown
between the aggregation ability of 5Ab42 and the aggregation
ability of synthetic Ab1–42 at 3 lM for 1 h incubation
(Fig. 1G). Additionally, mutant form of the 5 Ab42 is much
less harmful to HT22 neuroblastoma cell cultures than syn-
thetic Ab1–42 at the same concentration as expected
[Fig. 1H, Ab1–42(S) vs. 5Ab42(M), P < 0.05].
3.2. Expression of 5Ab in transgenic plants
We cloned 5Ab42 into three diﬀerent binary vectors: pMBP,
pAT and pE35S, all of which possess the nptII gene for selection
on kanamycin. We were attempting to develop a vector system
with the highest possible 5Ab42 expression in the transgenic po-
tato tubers. The 35S promoter was applied for strong and con-
stitutive expression (pMBP5Ab); the patatin promoter was also
used for tuber-speciﬁc expression (pAT5Ab). The double 35S
promoter, TEV 5 0-UTR, the signal peptide linked to the 5 0
end of 5Ab42, and the ER retention peptide linked to the 3 0
end of 5Ab42 were used to enhance accumulation and transla-
tion (pE5AbS) (Fig. 2A). Transgenic potatoes were obtained
through kanamycin selection and were conﬁrmed by PCR (data
not shown). Most of the transformed plants were found to grow
successfully with no phenotypic abnormalities, which indicated
that the expression of tandem-repeated 5Ab42may not interfere
with the growth and viability of the plants. These results areFig. 2. Construction and production of transgenic potatoes. (A) Schematic d
control of 35S CaMV promoter (35S pro), patatin potato tuber-speciﬁc pr
Transcription was terminated at the 3 0 region from the A. tumefaciens nopali
UTR, tobacco etch virus 5 0-UTR. Hexapeptide ER retention signal (SEK
transgenic plant lines. Equal amounts of total RNA were loaded and hybrid
The intensities of the transcripts indicated the strength of the promoters. NC,
of pE5AbS lines. Multiple and random integration are shown. (D) Western
loaded and 5Ab42 was detected by Ab-speciﬁc antibody, 4G8. (E) Quantitati
performed with each transgenic plant TSP. The results were consistent withconsistent with the results of a previous report [27]. The proper
transcription and translation of the 5Ab42 genes from diﬀerent
transgenic plants lines were conﬁrmed by Northern blot and
genomic Southern blot analysis. A total of 10 transgenic lines
from 3 diﬀerent constructs were selected: 3 lines of pMBP5Ab
(#1, 3 and 6), 4 lines of pAT5Ab (#1, 2, 3 and 5) and 3 lines
of pE5AbS (#1, 2 and 8). From the results of Northern blot
analysis, the transformants containing 5Ab42 controlled by
the double 35S promoter with the TEV 5 0-UTR leader sequence
evidenced higher 5Ab42 transcription levels than did the trans-
formants which harbored the 5Ab42 gene under the control of
either the patatin promoter or the single 35S promoter (Fig. 2B,
lanes 8–10). We detected no signiﬁcant diﬀerences in the b-amy-
loid expression levels between the pMBP5Ab- and pAT5Ab-
expressing transgenic tubers. In order to determine the transfer
DNA (T-DNA) copy numbers and the integration pattern of
pE5AbS (which shows the highest 5Ab42 expression among
all of the transformants), the genomic DNA was isolated, di-
gested with SalI, and hybridized with a 5Ab42-speciﬁc probe.
The pattern of genomic Southern blotting indicated that the
insertions had occurred at random sites throughout the genome
and copy number was more than 4 (Fig. 2C).
Multiple b-amyloid (5Ab) proteins expressed in transformed
potato tubers were analyzed by Western blotting (Fig. 2D).
Total soluble proteins were extracted from the tubers of the
individual transformed potato plants expressing pMBP5Ab,
pAT5Ab, and pE5AbS. 100 lg of TSP was loaded onto 12%
SDS–PAGE, and was then subjected to immunoblot analysis
with the 4G8 antibody. The amount of 5Ab42 expression from
transgenic plants lines was consistent with the level of transcript
determined by Northern blot analysis (Fig. 2B vs. D). Using
direct ELISA assays, we estimated the levels of 5Ab42 proteiniagram of expression cassettes. The 5Ab42 gene was cloned under the
omoter (PAT pro), and the dual enhancer 35S (E35S pro) promoter.
ne synthase gene (NOS ter) and the 35S CaMV gene (35S ter). TEV 5 0-
DEL) were used in the pE5Ab vector. (B) Northern blot analysis of
ized by a 5Ab42-speciﬁc probe. All samples contained the 5Ab42 gene.
non-transgenic potato as negative control. (C) Genomic Southern blot
blot analysis of transgenic plant lines. An equal amount of TSP was
ve analysis of expressed 5Ab42 in transgenic plants. Direct ELISA was
Western blot analysis.
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vectors. In the pAT5Ab transgenic lines, we conﬁrmed slightly
higher 5Ab protein expression levels, as compared to that ob-
served in the pMBP5Ab transgenic lines. This indicates that
the patatin promoter, a tuber-speciﬁc promoter which drives
Ab expression in the potato, is stronger than the CaMV35S
promoter, a constitutional expression promoter. The most pro-
found b-amyloid expression was observed with pE5AbS line
#2, which has the translation enhancer of the tobacco etch virus
(TEV) and a cleavage plant signal peptide, which were added at
the N-terminus of 5Ab42. pE5AbS line #2 also possesses an ER
retention signal, designated SEKDEL, which is added at the
C-terminus. The highest 5Ab42 expression in tuber tissue was
approximately 77.0 lg/ml of the applied extract in pE5AbS line
#2 (Fig. 2E). These data indicate that the double 35S promoter,
along with the TEV 5 0-UTR, may trigger an increase in the
expression of the 5Ab protein in pE5AbS transgenic plants.
Additionally, a combination of the signal peptide and the SEK-
DEL extension appears to result in the most pronounced accu-
mulation of the multimeric form of 5Ab in the plant cells. The
antigen, modiﬁed with a carboxyl-terminal SEKDEL exten-
sion, was found to accumulate in the potato tubers at a higher
level than did the unmodiﬁed antigen [31,32]. Finally, we se-
lected pE5AbS line #2 as material which would be used for fur-
ther mice immunization.CTL
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Our ﬁrst objective was to ascertain whether oral administra-
tion of the multimeric form of Ab1–42 was capable of inducing
an immune response, and eventually clearing Ab deposition in
AD model mice. In groups of ten, Tg2576 mice were immu-
nized with extracts from transgenic potato line pE5AbS #2
with non-transformed potato as control. The line #2 tuber ex-
tracts was estimated to contain about 0.9 lg of speciﬁc Ab1–42
protein per milligram of TSP. We used about 25 mg of TSP per
feeding, and included CTB as an adjuvant. Mice fed on plant-
derived 5Ab42 developed primary serum antibody responses
after the ﬁrst dose. The sera of the immunized mice with the
non-transformed plant extracts exhibited no induction of
cross-reactive antibodies (Fig. 3A). Antibody serum responses
persisted at high levels after the initial feeding of mice with ex-
tracts from transgenic line #2 for up to 9 weeks. After that
time, the mice were sacriﬁced to allow for analyses of their
brains. After boosting with 15 lg of synthetic Ab1–42 peptide
emulsiﬁed in alum at week 7, we noted no further increases in
the levels of serum 5Ab-speciﬁc antibodies. Weiner and his col-
leagues reported that Tg2576 mice showed immune hypo-
responsiveness to human Ab40 peptide because of impaired
immune systems [33]. Our results suggest that plant-derived
5Ab42 plus CTB activated Ab42-speciﬁc T cells to provide
assistance in the production of antibodies.**
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a reduction of Ab levels in animal brains, as well as behavioral
changes [11]. In order to determine the eﬀects of plant-derived
5Ab on the number of amyloid plaques in the brains of chal-
lenged mice, we counted the plaques in the brains of Tg2576
mice which had been fed plant-derived 5Ab42 and CTB
(Fig. 3B–D). Our analysis of the brains of the challenged mice
revealed an eﬀective reduction of existing plaques in the #2
feeding group, but this reduction was not observed in the con-
trol group. The plaque number and the % area of plaque (bur-
den) were signiﬁcantly reduced in #2 immunized mice (Fig. 3B
and C), but the average plaque size was not changed (Fig. 3D).
These results indicated that plant-expressed 5Ab and CTB not
only induces a humoral immune response, but also aﬀects the
clearance of plaques from the brain.4. Discussions
Few published reports have made special mention of any
relationship existing between the expression of foreign proteins
and phenotype abnormalities. This would appear to suggest
that the expression of foreign proteins exerts no signiﬁcant ad-
verse eﬀects on the growth of plants [34–36] or interferes with
plant growth and viability [37,38]. Beta-amyloid is toxic to cul-
tured cells, but the most of the 5Ab42-transformed plants were
found to grow successfully with no phenotypic abnormalities.
These results are consistent with the results of a previous re-
port [27], which indicated that the expression of b-amyloid
protein in potato plants exerts no adverse eﬀects on either
shoot growth or tuberization, not only under in vitro condi-
tions, but also under the conditions normally observed in a
greenhouse.
In our transformed potatoes, the double 35S promoter ap-
pears to be more active than any other promoters. Sometimes,
however, the presence of 35S promoter resulted in higher levels
of expression than did the double 35S promoter [39,40]. This
indicates that the expression of a speciﬁc antigen, when driven
by a diﬀerent promoter, can also be aﬀected by the nature of
the antigen. Additionally, the expression of foreign genes in
the diﬀerent transgenic lines with the same expression vector
appeared to vary according to the sites of their integration into
the genomic DNA, as well as the copy number (Fig. 2B, C, and
D for pE5AbS). The T-DNA insertion patterns reported in
this study were diﬀerent from the simple insertion patterns
which are commonly seen in association with Agrobacterium
transformation. Olhoft and Somers [41] reported that all of
the analyzed T0 plants exhibited multiple copies of a number
of transgene-hybridizing fragments. They concluded that the
observed multiple integration of T-DNA could be attributed
to the nature of the binary plasmid.
Our studies indicate that the oral introduction of 5Ab potato
extract with adjuvant into mice stimulated a primary immune
response, but we noted no strong or robust response after
boosting at week 7. In several reports, an immediate and
strong secondary antibody response has been observed in ani-
mals receiving a booster of a commercial vaccine, as memory
immune cells had apparently been established as a result of
oral immunization [22,42]. In the case of Tg2576 transgenic
mouse immunization, the impaired adaptive immune response
was associated with Ab1–40 [33].We used CTB as an adjuvant; CTB is a nontoxic subunit of
cholera toxin which has been shown to act as a non-T helper
(Th) 1-inducing adjuvant. In an initial clinical trial with
Ab1–42 (AN-1792) conducted by Elan Corp., QS-21, a Th1
adjuvant, was used as adjuvant. Phase IIa trials were halted be-
cause some of the patients showed meningoencephalitis due to
inﬂammation in the brain through T-cell hyper-activation.
Some researchers predict that Ab1–42 has both B-cell and T-
cell epitopes that would be expected to result in extensive T-cell
activation. Therefore, CTB is a more potent adjuvant for Ab
immunization studies [43]. We have not observed any brain
inﬂammatory symptoms in the brains of our mice (unpub-
lished results).
This study is an example of active immunization for AD,
and also represents a unique approach, in which transgenic
plants are used to produce a vaccine. The clinical peptide vac-
cine trials were canceled due to adverse eﬀects. As in most
other Ab immunotherapy trials, this trial has taught us that
the optimization of a vaccine must circumvent or eliminate del-
eterious eﬀects, while maintaining the elicitation of a highly
speciﬁc immune response to Ab. In this study, we have sug-
gested two possibilities for the elimination or amelioration of
adverse eﬀects. One involves the modiﬁcation of wild-type
Ab1–42. We used the multimeric variant of Ab, with a modi-
ﬁed sequence used as the antigen. Oral vaccines act by stimu-
lating the immune system at eﬀector sites (lymphoid tissue)
located in the gut, and the gut immune system suppresses
Th1 responses and enhances Th2 responses [21,44]. Therefore,
we plan to conduct further studies in order to determine the
manner in which transgenic potatoes expressing 5Ab42 can
be used in the development of an edible vaccine against Alzhei-
mers disease.
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